GENSCRIPT BIO (01548) releases annual financial results, with a net loss attributable to shareholders of 533 million USD, a year-on-year shift from profit to loss.

GENSCRIPT BIO (01548) announced its annual performance for the year ended December 31, 2025. The group achieved revenue of 960 million US dollars, an increase of 61.4% compared to the previous year. The loss attributable to owners of the parent company was 533 million US dollars, a turnaround from profit to loss; with a basic loss per share of 24.58 cents. During the reporting period, the group achieved significant revenue growth, mainly attributed to a significant increase in licensing revenue, and other businesses also achieved steady growth. The revenue growth drove a substantial increase in the group's gross profit. The group's gross profit from continuing operations for the reporting period was approximately 553 million US dollars, an increase of 103.3% from the previous period.